Fatal Hypogammaglobulinemia 3 Years after Rituximab in a Patient with Immune Thrombocytopenia: An Underlying Genetic Predisposition?

We report the case of a young woman who developed, 3 years after stopping Rituximab (RTX) prescribed for immune thrombocytopenia (ITP), a severe immunodeficiency leading to fatal pulmonary Epstein–Barr virus-positive diffuse large B-cell lymphoma. Genetic analysis led us to identify four missense mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Viallard, Jean-François, Parrens, Marie, Rieux-Laucat, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949674/
https://www.ncbi.nlm.nih.gov/pubmed/31956452
http://dx.doi.org/10.1155/2019/2543038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949674/
https://www.ncbi.nlm.nih.gov/pubmed/31956452
http://dx.doi.org/10.1155/2019/2543038

Ejemplares similares